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CASE REPORT

Open Access

Cardiovascular magnetic resonance with an MR
compatible pacemaker
Anita R Bhandiwad1*, Kristopher W Cummings2, Michael Crowley2 and Pamela K Woodard2

Abstract
Magnetic resonance imaging (MRI) within FDA guidelines for the MRI-conditional pacemaker precludes placing the
heart at the center of the magnet’s bore. This in effect appears to preclude cardiovascular MR. In this manuscript,
we describe a protocol for cardiovascular MR of patients with a Revo pacemaker system while operating within
FDA guidelines, and the first US case of cardiovascular MR in a patient with a Revo MRI-conditional pacing system
despite position constraints.
Keywords: MRI-conditional pacemaker, Cardiovascular magnetic resonance, Revo pacer

Background
Several million people are estimated to currently have
cardiac implantable electronic devices (CIEDs), including
pacemakers and implanted cardioverter defibrillators
(ICD). This number may continue to grow with expanded
indications for heart failure and primary prevention.
Historically, CIEDs have been considered to be absolute
contraindications for magnetic resonance imaging (MRI).
However, there is an estimated 50–75% probability
that MRI will be indicated for a patient over the device
lifetime [1].
There are several concerns regarding the interaction of
these devices with the static and pulsed magnetic field.
First, the generator or leads may be displaced, although
translational forces and torque on the leads have been
shown to be small at 1.5 Tesla field strength [2]. Next, the
behavior of the device and programming may be altered.
For instance, pacemakers may change to asynchronous
pacing mode or an ICD may temporarily suspend detection and therapies of ventricular tachyarrhythmias. Pulsed
radiofrequency from the MRI may induce voltage pulses
that result in oversensing of electrical signals in the magnetic field. Alternatively, pacing inhibition in a pacemakerdependent patient, unintended cardiac stimulation, and
possible inappropriate shocks could result [1,3,4]. Finally,
radiofrequency-induced heating of myocardial tissue near
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the pacemaker lead tip has the potential to cause thermal
injury with resultant pacing threshold deterioration or
even atrial or ventricular perforation [2]. Therefore, even
nonfunctioning leads left without connection to a generator
or epicardial leads have been considered a contraindication
to MRI.
Device programming can mitigate some of these potential risks. However, electrical reset can occur in up to 6%
of pacemaker patients undergoing MRI upon exposure to
a magnetic field that overrides programming changes
[2,5]. Pacemaker inhibition could lead to bradycardia/asystole, or competitive rhythms may occur that can induce
fatal tachyarrhythmias [2,4].
Although MR conditional pacemaker, ICD, cardiac
resynchronization therapy pacemaker and defibrillator
systems are available in Europe and some in Asia, most
are investigational in the United States (Biotronik, Berlin,
Germany, and St. Jude Medical, St. Paul, Minnesota).
Most recently, development and Food and Drug Administration (FDA) approval of the MRI-conditional device, the
Medtronic Revo pacing system (Medtronic, Minneapolis,
Minnesota), has been a notable advance. Conditions for
scanning patients with the Revo system within FDA
guidelines include a 6-week delay after pacemaker implantation, 1.5 T static magnetic field strength, maximum
specific absorption rate (SAR) of 2 W/kg for each sequence, and maximum slew rate of 200 T/m/s. MR scanning within FDA guidelines for the device precludes
placing the heart at the magnet isocenter (center of bore).
However, the pacemaker system may pass through
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Figure 1 SSFP coronal scout with isocenter below T12. Position
confirmed by inferior rib while placing patient in scanner. Note the
relatively higher signal at the image isocenter (arrow).

isocenter during table positioning. Isocenter must be
above the superior surface of the C1 vertebra or below the
inferior surface of the vertebral body of T12 [4]. This in
effect appears to preclude cardiovascular MR (CMR). In
this manuscript, we describe a protocol for CMR of
patients with a Revo pacemaker system while operating
within FDA guidelines, and the first US case of CMR in a
patient with a Revo MRI-conditional pacing system despite position constraints.

Figure 2 Still-frame from cine steady-state free precession
image. Localized artifact from sternal wires (dashed arrow) and
pacemaker lead in right ventricle (solid arrow).

Figure 3 Late gadolinium enhancement images demonstrating
enhancement in the inferior and lateral walls. Findings
consistent with infiltrative process and biopsy-confirmed PTLD (solid
arrows), and pacemaker lead in right ventricle (dashed arrow).

Case presentation
A 34-year-old woman had a history of an anterior
myocardial infarction following spontaneous left anterior
descending coronary artery dissection 11 days postpartum at age 28 and subsequently underwent cardiac

Figure 4 Late gadolinium enhancement image on CMR study 4
months later. Slight improvement in inferior and lateral
enhancement (solid arrows).
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transplantation. She was found to have chronic inflammation and episodes of acute rejection on endomyocardial
biopsies. Echocardiography demonstrated abnormal
diastolic function with restrictive filling and course was
notable for development of clinical heart failure requiring hospitalization. Biopsies confirmed post-transplant
lymphoproliferative disorder (PTLD) consistent with
plasmacytoma. CMR demonstrated patchy areas of
late gadolinium enhancement (LGE) in the inferior,
inferoseptal and lateral walls of the left ventricle consistent with infiltrative process. The patient’s course was
further complicated by development of sinus node
dysfunction with sinus pauses of 4.5 seconds. Pacemaker implantation was advised. MRI-compatible dualchamber system was implanted due to the anticipated
need for future CMR studies to follow cardiac allograft
involvement with chemotherapy [6].
The patient was referred for CMR 6 months after pacer
implantation. The scan was performed on 1.5 T whole
body scanner (TIM Symphony, Siemens Medical Systems,
Malvern, NJ), slew rate 125 T/m/s. A cardiologist, radiologist and MRI physicist were present. Isocenter was placed
inferior to T12, determined by the inferior rib (Figure 1).
Minor modifications to the flip angle of the cine steadystate free precession (SSFP) sequences were made to
maintain SAR < 2 W/kg. The table position was set to
“FIXED” to prevent default movement. Prior to scanning,
the device was interrogated: atrial lead impedance 568
ohms, ventricular lead impedance 472 ohms, atrial lead
capture threshold 1 V at 0.4 ms, ventricular lead capture
threshold 1 V at 0.4 ms, P-wave amplitude sensing
3.4 mV, R-wave amplitude sensing 10.3 mV. The device
was switched to “SureScan On” and ODO mode.
Following completion of imaging, device was set to
“SureScan Off” and DDD mode, and interrogation showed
no significant change in parameters: atrial lead impedance
544 ohms, ventricular lead impedance 472 ohms, atrial
lead capture threshold 1 V at 0.4 ms, ventricular lead
capture threshold 1 V at 0.4 ms, P-wave amplitude sensing
3.5 mV, R-wave amplitude sensing 9.9 mV. The patient
was monitored throughout the study by telemetry, blood
pressure, and voice communication. The patient had no
complaints during scanning.
A complete CMR study without and with contrast was
performed with black blood half-fourier acquisition
single-shot turbo spin-echo (HASTE) scout imaging, cine
SSFP sequences (TR 3.0 ms, TE 1.3 ms, flip angle < 90°
modified to maintain SAR <2 W/Kg) in the 2 and 4chamber long-axis and short axis cardiac planes, followed
by segmented gradient-recalled phase sensitive inversion
recovery (PSIR) LGE short and long axis imaging (TR
46 ms, TE 3.4 msec, flip angle 15°, IR time 280 msec)
performed after intravenous administration of 0.2 mmol/
Kg gadoversetamide (Optimark, Covidien, St. Louis, MO).
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These images demonstrated patchy LGE of the left ventricular inferior and lateral walls consistent with infiltrative
process and known PTLD. Localized artifact from the
pacemaker lead in the right ventricle was present without
effect on interpretability of images (Figures 2 and 3).
Four months later the patient was referred again for
CMR to assess response to therapy. A similar protocol
as described above was performed. These images
demonstrated slight interval decrease in enhancement
pattern (Figure 4).

Conclusion
Quarta et al. described CMR with the MRI-conditional
pacing system performed in Europe where positioning
restrictions are not required [7]. Following appropriate
U.S. imaging protocols for this device, diagnostic quality
cardiac images can be obtained despite position of
isocenter remote from the heart. Localized artifact from
leads does not compromise image interpretability. The
MRI-conditional pacemaker system may allow the
benefits of MRI to be more accessible to pacemaker
patients.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
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